BridgeBio Stock Surges on Positive Dwarfism Drug Data. It’s Bad News for BioMarin.


This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit

  • Order Reprints
  • Print Article

BridgeBio Pharma stock was soaring after the biopharmaceutical company reported positive results in a Phase two clinical trial for an experimental treatment for achondroplasia, the most common type of short-limbed dwarfism.

On Monday, BridgeBio (ticker: BBIO) said in a news release that its experimental drug Infigratinib showed an annualized improvement of 3.03 centimeters in so-called height velocity, or gains in height, in a study including 10 children.


Please enter your comment!
Please enter your name here